Rheumatoid Disease

Rheumatoid Disease, also known as Rheumatoid Arthritis (RA), belongs to a category of conditions called autoimmune rheumatic musculoskeletal diseases—systemic inflammatory conditions in which the immune system mistakenly attacks the body’s own tissues. Unlike osteoarthritis, which results from mechanical wear and tear, rheumatoid arthritis is driven by the immune system and produces inflammation not only in joints but potentially in other organs throughout the body. It is the most prevalent form of inflammatory arthritis globally.

Rheumatoid arthritis—also called rheumatoid disease—is a chronic, systemic autoimmune disease in which the immune system attacks the synovium, the thin membrane lining the inside of joints. This causes inflammation, pain, swelling, stiffness, and, without adequate treatment, progressive joint destruction and disability. The disease typically affects multiple joints symmetrically—meaning the same joints on both sides of the body are involved simultaneously. Small joints of the hands, wrists, and feet are commonly affected first. RA can also cause inflammation in other organs, including the lungs, heart, eyes, blood vessels, and skin, making it a truly systemic disease rather than a condition of joints alone.

Rheumatoid arthritis affects approximately 1.3 million Americans and 17.6 million people worldwide as of 2020—a figure that has increased by 121% since 1990, driven primarily by an aging and growing global population. The global burden is projected to reach 31.7 million by 2050. RA is more common in women, with females developing it approximately 2.5 times more often than males. The peak age of onset is the 60s and 70s, though the disease can begin at any age, including childhood. Cardiovascular disease, accelerated by the systemic inflammation of RA, is the most common cause of death in patients with rheumatoid arthritis. Respiratory disease—particularly lung involvement—is the second leading cause of RA-related mortality, affecting 30–40% of patients to some degree. With modern treat-to-target (TTT) therapy, many patients achieve remission or low disease activity and live full, productive lives.

• Seropositive RA: approximately 60–80% of all cases. Patients carry one or both of the characteristic RA autoantibodies: rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA, also called anti-CCP antibodies). Seropositive RA is generally associated with more aggressive, erosive joint disease, higher rates of extra-articular complications (including rheumatoid nodules, lung disease, and vasculitis), and worse long-term functional outcomes.
• Seronegative RA: approximately 20–40% of all cases. Both RF and anti-CCP antibodies are negative. The diagnosis is based entirely on clinical and imaging findings, and other inflammatory arthropathies (including psoriatic arthritis and crystal-related arthritis) must be carefully excluded. Prognosis is more variable than in seropositive disease.

• Early RA: symptom onset and diagnosis within the first six months. This is the most critical period in the disease: aggressive treatment during this six-month window of opportunity can prevent irreversible structural joint damage and significantly improve long-term outcomes.
• Established RA: This is when the disease is present for more than six months, with confirmed persistent synovitis or documented joint damage.
• Palindromic rheumatism: episodic, self-resolving attacks of joint inflammation without permanent structural damage. Recognized as an RA precursor in genetically susceptible individuals, particularly those who test positive for anti-CCP antibodies.
• Felty’s syndrome: a rare, advanced complication (1–3% of seropositive RA patients) characterized by the triad of RA, spleen enlargement (splenomegaly), and abnormally low white blood cell counts (neutropenia). Associated with recurrent infections, rheumatoid nodules, liver enlargement, and lung involvement.
• Juvenile idiopathic arthritis—RF-positive polyarticular type (JIA-RF+): the childhood form of RA, beginning before age 16. Biologically indistinguishable from adult seropositive RA, it carries the highest risk of erosive joint damage among all pediatric arthritis subtypes.

Disease activity is measured at every clinical visit using validated scoring instruments. The primary target of treatment—called treat-to-target—is remission, defined as a Disease Activity Score-28 with C-reactive protein (DAS28-CRP) below 2.6, or equivalent low scores on other validated tools. Low disease activity (DAS28-CRP at or below 3.2) is the minimum acceptable target when remission cannot be achieved. Moderate disease activity (DAS28-CRP 3.2 to 5.1) and high disease activity (DAS28-CRP above 5.1) both indicate that treatment needs to be escalated.

Rheumatoid arthritis has no single identifiable cause. Current evidence supports a multi-hit model in which genetic predisposition, environmental triggers, and immune dysregulation interact over years—sometimes decades—before clinical arthritis appears.

The strongest genetic risk factor for RA is a specific region of the immune system’s human leukocyte antigen (HLA) genes—specifically certain variants of the HLA-DRB1 gene called the “shared epitope.” These variants shape the antigen-binding groove of immune recognition proteins in a way that preferentially presents citrullinated (chemically modified) peptides to CD4+ T-cells, initiating the autoimmune cascade. Several other genes also contribute, including PTPN22 (which promotes survival of self-reactive T-cells), STAT4 (which drives inflammatory cytokine production), and CTLA4 (which disrupts the normal checkpoint that prevents T-cells from attacking self-tissue). More than 100 genetic locations outside the HLA region have been identified as contributing to RA susceptibility. Genetics account for approximately 60% of RA heritability.

The leading environmental trigger is cigarette smoking. Smoking activates enzymes called PAD2 and PAD4 in the lungs that chemically modify proteins through a process called citrullination—converting arginine amino acid residues to citrulline. These citrullinated proteins are recognized as foreign by the immune system in genetically susceptible individuals, triggering the production of anti-citrullinated protein antibodies years before any joint symptoms develop. Periodontitis (gum disease) contributes through a similar mechanism: the bacterium Porphyromonas gingivalis produces its own protein-arginine deiminase (PAD) enzyme, generating oral citrullinated proteins that can prime the same autoimmune response. Gut microbiome imbalances—particularly an overgrowth of certain bacterial species—are also associated with immune activation leading to ACPA production. Viral infections, including Epstein-Barr virus (EBV) and parvovirus B19, have been implicated as additional triggers.

Once autoantibodies (ACPA and RF) are present, immune complexes form and deposit in the joint’s synovial membrane. This triggers complement activation, recruits inflammatory cells—neutrophils, macrophages, T-cells, and B-cells—into the joint space, and releases a cascade of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-1beta), IL-6, and IL-17. The synovium’s structural cells (fibroblast-like synoviocytes) respond to these signals by proliferating and forming an invasive, tumor-like tissue mass called pannus—from the Latin word for cloth. The pannus secretes enzymes called matrix metalloproteinases (MMPs) that degrade cartilage, and signals called RANKL that activate osteoclasts (bone-destroying cells) to erode the bone adjacent to the joint. The tissue damage in RA is caused not by the bacteria or virus directly but by this sustained, misdirected immune response—which is why anti-inflammatory and immune-suppressing treatments are so central to management.

• De fumar: the best-evidenced modifiable risk factor. Smoking accounts for 7.1% of RA-related disability worldwide. Smoking worsens established disease and reduces the effectiveness of both disease-modifying antirheumatic drugs (DMARDs) and biologic treatments. Cessation is the single most impactful modifiable action a person at risk—or living with RA—can take.
• Obesidad: Increased body mass index (BMI) is associated with elevated RA risk in a dose-dependent relationship (higher BMI = higher risk). Obesity also reduces the response to multiple drug treatments and is associated with higher disease activity.
• Periodontitis: Chronic gum disease is associated with increased RA risk through the citrullination mechanism described above. Regular dental care is a meaningful prevention strategy.
• Diet quality: Emerging evidence supports that pro-inflammatory diets are associated with higher RA risk. A Mediterranean-style diet is conditionally recommended by the American College of Rheumatology (ACR) 2022 guidelines.

• Female sex: Women develop RA approximately 2.5 times more often than men. Hormonal and reproductive factors contribute; the global age-standardized female rate is 293.5 per 100,000 versus 119.8 per 100,000 in males.
• Older age: Risk increases progressively with age, with onset most common in the 60s and absolute prevalence peaking between ages 75 and 79 (828.2 per 100,000 globally).
• Family history: First-degree relatives of RA patients have meaningfully elevated risk. Genetics contribute approximately 60% of RA heritability.
• HLA-DRB1 shared epitope genotype: The risk is compounded when the shared epitope gene variant is combined with smoking or obesity.
• Nulliparity: Women who have never given birth face a greater risk than women who have.
• Maternal smoking: Children of mothers who smoked have double the adult RA risk, suggesting intrauterine immune programming effects.
• Lower parental socioeconomic status: Early-life economic deprivation is associated with elevated adult RA risk, possibly through effects on immune system development.

• Breastfeeding: Women who have breastfed have a reduced risk of developing RA compared to those who have not.

There is no population-level screening program for rheumatoid arthritis analogous to cancer or blood pressure screening. Targeted case-finding and early detection are the practical approaches, focused on patients who present with suspicious symptoms. Clinicians should consider an RA evaluation—and refer to rheumatology—in any adult presenting with unexplained joint swelling in one or more joints, morning stiffness lasting more than 30 minutes, symmetrical small-joint involvement, or elevated inflammatory markers (erythrocyte sedimentation rate—ESR or CRP) without a clear infectious cause, particularly when symptoms have lasted six weeks or longer.
When RA is suspected, the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria provide a scoring framework: a total score of 6 or more out of 10 points indicates definite RA. Points are assigned based on the number and size of affected joints (0 to 5 points), serologic results for RF and anti-CCP antibodies (0 to 3 points), elevated acute-phase reactants (0 to 1 point), and symptom duration of six weeks or more (1 point). The key serology tests are anti-CCP antibodies (sensitivity 81.7%, specificity 96.7%—the most specific single RA test available) and rheumatoid factor (sensitivity 75%, specificity 78.3%). Combining both RF and anti-CCP testing achieves 88.3% sensitivity and 95% specificity. Musculoskeletal ultrasound with power Doppler imaging can detect subclinical joint inflammation (synovitis) not yet visible on physical exam, making it particularly valuable in early disease evaluation.

Rheumatoid disease cannot currently be prevented—no vaccine exists. However, addressing modifiable risk factors substantially reduces both the probability of developing the disease and the severity if it occurs:

• Smoking cessation: strongly recommended for all at-risk patients. Cessation reduces RA incidence risk and improves disease outcomes in those already diagnosed.
• Periodontal care: Treating and maintaining gum disease reduces the chronic oral citrullination burden that can prime the autoimmune response.
• Weight management: Maintaining a healthy BMI reduces both RA risk and the severity of disease activity.
• Mediterranean-style diet: This is conditionally recommended by the ACR 2022 guidelines as associated with reduced systemic inflammation.
• Early diagnosis within the six-month window: the most important secondary prevention step. Initiating treat-to-target therapy in the first six months of disease significantly prevents irreversible structural joint damage and long-term disability.
• Cardiovascular risk factor management: mandatory secondary prevention given the two-fold elevated myocardial infarction risk in RA. Blood pressure control, statin therapy, smoking cessation, and regular cardiovascular screening are all part of comprehensive RA management.
• Vaccination before starting immunosuppression: Pneumococcal, influenza, shingles (non-live formulation), and hepatitis B vaccines are recommended before initiating biologic or other immunosuppressive therapies.

The hallmark symptom that most reliably distinguishes rheumatoid disease from non-inflammatory joint diseases is prolonged morning stiffness lasting more than 30 minutes—often more than an hour in active disease. This “gelling” phenomenon, in which the joints feel stiff and difficult to move after a period of rest, reflects active synovial inflammation and is characteristic of RA. In contrast, stiffness from osteoarthritis (wear-and-tear arthritis) typically resolves within 30 minutes. This morning stiffness is accompanied by symmetrical joint pain, swelling, and warmth—meaning the same joints on both sides of the body are affected simultaneously.

• Morning stiffness lasting more than 30 minutes, often more than one hour in active disease
• Symmetrical joint swelling: both hands, both wrists, and both feet typically affected at the same time
• Joint pain and tenderness on touch and movement
• Joint warmth and sometimes redness over affected joints
• Reduced range of motion: difficulty making a fist, combing hair, buttoning clothing, walking normally
• Small joints most commonly involved first: knuckles (metacarpophalangeal and proximal interphalangeal joints), wrists, and the toe joints at the ball of the foot (metatarsophalangeal joints)
• Cervical spine involvement: Advanced disease can affect the atlantoaxial joint at the top of the neck, creating a risk of spinal cord compression that requires specialist monitoring and sometimes surgery.

Without adequate treatment, persistent synovial inflammation damages the structures that stabilize joints, leading to characteristic deformities. Ulnar deviation describes a wind-swept appearance in which the fingers deviate toward the little finger side at the large knuckles. Boutonniere deformity is a bent middle finger joint (proximal interphalangeal—PIP flexion) combined with a hyperextended fingertip joint (distal interphalangeal—DIP hyperextension). Swan-neck deformity is the reverse: a hyperextended middle joint and a bent fingertip. Z-deformity of the thumb, volar subluxation of the knuckles (forward slipping of the finger bones at the knuckle), and hallux valgus (bunion deformity) of the foot are also common in established disease. Modern DMARD therapy has substantially reduced the frequency of these deformities.

• Fatiga: often severe and one of the most disabling and underrecognized features of RA; frequently described as a major driver of reduced quality of life
• Low-grade fever during active disease flares
• Loss of appetite and unintentional weight loss
• Malaise and general weakness
• Anemia of chronic disease: low red blood cell counts resulting from chronic systemic inflammation; causes pallor and worsens fatigue

Between 18 and 41% of RA patients develop extra-articular (outside the joints) manifestations at some point during their disease. Severe extra-articular disease occurs in 1.5–21.5%. These manifestations affect nearly every organ system and are more common in long-standing seropositive disease.

• Rheumatoid nodules: firm, painless lumps under the skin at pressure points, most commonly on the outer side of the elbow, fingers, heel, and spine. The most common extra-articular manifestation, associated with severe seropositive RA.
• Interstitial lung disease (ILD): progressive scarring of lung tissue; subclinical in many patients, but 30–40% of RA patients have some respiratory involvement on imaging. A leading cause of RA-related death. Requires high-resolution computed tomography (CT) of the chest for characterization.
• Cardiovascular disease: accelerated atherosclerosis (hardening of the arteries) driven by chronic systemic inflammation; two-fold increased risk of myocardial infarction (heart attack); up to 50% increased cardiovascular mortality compared to the general population
• Rheumatoid vasculitis: inflammation of small to medium blood vessels; can cause skin ulcers, damage to multiple peripheral nerves simultaneously (mononeuritis multiplex), and digital infarcts (tissue death at the fingertips). Seen in severe, long-standing seropositive disease.
• Sicca symptoms: Dry eyes and dry mouth from secondary Sjogren’s syndrome overlap (approximately 30% of RA patients have some degree of secondary Sjogren’s).
• Scleritis and episcleritis: painful inflammation of the white of the eye. Scleritis can threaten vision and requires urgent evaluation.
• Pericarditis and pleural effusion: inflammation of the sac around the heart (pericarditis) or fluid around the lungs (pleural effusion). It’s usually subclinical and detected incidentally on imaging.
• Neuropatía periférica: It is most commonly from carpal tunnel syndrome (nerve compression at the wrist) or from vasculitic nerve damage in severe disease.
• Secondary amyloidosis: It is a rare but serious long-term complication in which an abnormal protein called amyloid (produced by chronic uncontrolled inflammation) deposits in the kidneys, heart, and other organs, causing organ failure.

• In children and adolescents with RF-positive polyarticular JIA: The joint pattern mirrors adult RA—symmetric small-joint involvement, morning stiffness, and elevated inflammatory markers. Children are at risk for growth disturbances when major joints are involved during development, and jaw (temporomandibular joint) involvement can affect jaw growth.
• In adults aged 30 to 60 years (peak incidence in women): Onset is typically insidious, developing over weeks to months. Morning stiffness is usually the most reliable early complaint. Many patients are initially misdiagnosed with viral arthritis or fibromyalgia. Women often experience improvement during pregnancy, followed by post-partum flares.
• In older adults aged 60 to 79 years (peak age-standardized prevalence): Late-onset RA (beginning after age 60) can present with large-joint, proximal muscle involvement that closely resembles polymyalgia rheumatica—an important diagnostic distinction. Inflammatory markers (ESR, CRP) tend to be higher at onset. Comorbidity burden is substantially greater: more than 55% of older RA patients have five or more additional medical conditions, compared to 38% of age-matched non-RA individuals.

Rheumatoid disease is diagnosed by a rheumatologist—a physician specializing in immune-mediated musculoskeletal diseases. The goal is diagnosis and treatment initiation within six months of symptom onset to prevent irreversible joint damage. No single test confirms RA; the diagnosis requires combining clinical assessment, laboratory serology, and imaging findings using the 2010 ACR/EULAR classification criteria.

The rheumatologist assesses tender joint count and swollen joint count—typically across 28 joints (DAS28 assessment) or a full 66/68-joint evaluation. Grip strength, range of motion in affected joints, and functional capacity using the Health Assessment Questionnaire Disability Index (HAQ-DI, scored 0 to 3) are all documented. The HAQ-DI is also used to track function over time and treatment response.

• Anti-CCP (anti-cyclic citrullinated peptide) antibodies: the gold-standard serologic test for RA. Sensitivity 81.7%, specificity 96.7%, positive predictive value 96.1%. The most specific individual test available for RA. Also predicts erosive joint disease and extra-articular complications.
• Rheumatoid factor (RF): an IgM antibody against the Fc region of IgG; present in approximately 70–80% of RA patients. Sensitivity 75%, specificity 78.3%. Also elevated in other conditions, including hepatitis, Sjogren”s syndrome, and healthy older adults.
• Combined RF plus anti-CCP: sensitivity 88.3%, specificity 95%. Recommended together for the highest diagnostic accuracy.
• Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP): inflammatory markers that reflect disease activity, track flares, and contribute to disease activity scoring. CRP is more specific and responds more rapidly than ESR.
• Hemograma completo (CBC): screens for anemia of chronic disease (the most common RA-associated anemia), neutropenia (suggesting Felty syndrome), and thrombocytosis (elevated platelets in active disease). Also required for DMARD safety monitoring.
• Comprehensive metabolic panel: baseline liver and kidney function must be established before initiating any DMARD, as several drugs affect these organs. Ongoing monitoring is required during treatment.
• Uric acid: This test excludes gout, which can mimic RA, especially in seronegative presentations.
• Antinuclear antibody (ANA) and anti-dsDNA antibodies: These tests exclude systemic lupus erythematosus (SLE), which can overlap with RA or present similarly.
• HLA-B27: This test excludes spondyloarthropathies (including ankylosing spondylitis and reactive arthritis), which can cause inflammatory joint disease without RA’s typical serologic profile.

• Plain radiography (X-ray) of hands, wrists, and feet: first-line structural imaging. In early disease: periarticular bone thinning (osteopenia) around affected joints. In established disease: joint space narrowing (cartilage loss), and marginal erosions—small notches chipped out of the bone edges at the outer margin of joints. The modified Sharp/van der Heijde Score quantifies structural damage progression in clinical trials.
• Musculoskeletal ultrasound with power Doppler: the most sensitive clinical tool for detecting active joint inflammation, including subclinical synovitis not yet visible on physical examination. Power Doppler detects blood flow in the inflamed synovium, confirming active vascular inflammation. Also detects tenosynovitis (tendon sheath inflammation) and early erosions. No radiation; widely used in monitoring treat-to-target response.
• Imágenes por resonancia magnética (RM): highest sensitivity for early disease. Detects synovitis, bone marrow edema (called osteitis—inflammation inside the bone adjacent to the joint), tenosynovitis, and erosions before they appear on X-ray. Preferred for evaluating cervical spine atlantoaxial instability.
• High-resolution CT of the chest (HRCT): standard of care for detecting and characterizing RA-associated interstitial lung disease. Distinguishes the usual interstitial pneumonia (UIP) pattern from the non-specific interstitial pneumonia (NSIP) pattern—a distinction with important implications for treatment and prognosis.
• Dual-energy X-ray absorptiometry (DEXA) scan—bone density measurement: This is mandatory for patients on glucocorticoids and for all RA patients given elevated osteoporosis risk from both the disease and its treatments.

When a large joint is significantly swollen and the diagnosis is uncertain, joint aspiration (arthrocentesis)—withdrawing fluid from the joint with a needle—provides diagnostic information. Inflammatory synovial fluid in RA typically contains 5,000 to 50,000 white blood cells per microliter, predominantly neutrophils. Crystal analysis (looking for monosodium urate crystals of gout or calcium pyrophosphate crystals of calcium pyrophosphate deposition—CPPD disease) is critical for excluding crystal arthropathy, especially in seronegative presentations. Gram stain and culture exclude septic arthritis, which is a medical emergency requiring immediate antibiotic treatment and surgical drainage.

Rheumatoid disease is not curable, but it is highly manageable. The goal of treatment is to achieve and maintain remission or low disease activity using a treat-to-target strategy: monitoring disease activity with validated instruments at every clinical visit (typically every one to three months during active disease) and systematically adjusting therapy until the predefined target is reached. Early treatment within the six-month window of opportunity produces substantially better long-term structural and functional outcomes than delayed therapy. A multidisciplinary team—rheumatology, physical therapy, occupational therapy, cardiology, pulmonology, nursing, and orthopedic surgery as needed—provides the most comprehensive outcomes. Your rheumatologist will determine the most appropriate treatment combination and sequence for your specific disease activity, comorbidities, and preferences.

The 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis provides evidence-based recommendations for non-drug management. Consistent exercise is strongly recommended for all patients, as it improves physical function, reduces pain, and supports cardiovascular health—a critical priority given RA’s cardiovascular risk. Specific forms, including aerobic exercise (walking, swimming, cycling—150 minutes per week of moderate intensity), aquatic exercise (low-impact, reduces joint loading), resistance training (to maintain muscle strength around affected joints, prescribed by a physical therapist), and mind-body exercise such as yoga and tai chi, are all conditionally recommended. Comprehensive physical therapy addresses functional training, gait, and assistive device prescription. Occupational therapy provides joint protection education, adaptive equipment assessment, splinting, and vocational counseling. A Mediterranean-style diet is conditionally recommended over no structured diet. Cognitive behavioral therapy (CBT) is conditionally recommended for managing pain, depression, and anxiety. Self-management education programs reduce pain and disability while increasing patient self-efficacy and are conditionally recommended. Tobacco cessation is strongly recommended—it is the single most impactful modifiable intervention in RA, addressing both disease activity and cardiovascular risk simultaneously.

Disease-modifying antirheumatic drugs (DMARDs) are the backbone of RA pharmacotherapy. Unlike pain relievers or anti-inflammatory drugs, DMARDs address the underlying immune dysfunction driving the disease. The 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis defines the following first-line conventional synthetic DMARD (csDMARD) approach.

Methotrexate (brand names Rheumatrex, Trexall) is the anchor drug for RA and is strongly preferred as the initial treatment for moderate to high disease activity. It works by inhibiting a key enzyme in the folate pathway, producing antiproliferative and anti-inflammatory effects on immune cells. It is taken orally or by subcutaneous injection, titrated to a target dose of 15 mg or more per week over four to six weeks, and must always be accompanied by daily folic acid supplementation to prevent side effects. Liver function tests and CBC must be monitored every four to eight weeks. Methotrexate is teratogenic—it must be discontinued for at least three months before a planned pregnancy in either partner.

Hydroxychloroquine (Plaquenil®) is the preferred initial csDMARD for low disease activity, valued for its excellent tolerability and favorable safety profile. It works by altering lysosomal pH and modulating innate immune signaling. An annual ophthalmology examination is required to screen for the rare complication of retinal toxicity with long-term use. Sulfasalazine (Azulfidine®) is conditionally preferred over methotrexate for low disease activity and is less immunosuppressive. Leflunomide (Arava®) inhibits T- and B-cell proliferation and is an effective alternative to methotrexate; it has a very long half-life, requiring a specific drug elimination protocol before pregnancy. Methotrexate, hydroxychloroquine, and sulfasalazine can be used in combination as triple therapy—a regimen with long-term outcomes equivalent to biologic combinations in some trials and preferred in specific clinical settings.

When conventional DMARDs do not achieve the treat-to-target goal, biologic DMARDs (bDMARDs)—laboratory-engineered antibodies or fusion proteins targeting specific immune molecules—are added to or substituted for csDMARDs. The 2021 ACR guidelines treat bDMARDs and targeted synthetic DMARDs (tsDMARDs, described below) as equivalent options after csDMARD failure, with the choice guided by comorbidities, patient preferences, and drug safety profiles.

TNF inhibitors (TNFi)—five U.S. Food and Drug Administration (FDA)-approved agents—are the most frequently prescribed biologic class for RA globally. They work by blocking TNF-alpha, the cytokine that drives much of RA’s joint inflammation. Adalimumab (Humira®) is a fully human antibody given as a subcutaneous injection every two weeks; it has the most extensive biosimilar portfolio of any biologic. Etanercept (Enbrel®) is a fusion protein given as a weekly subcutaneous injection; it has the lowest risk of tuberculosis reactivation among TNFi. Infliximab (Remicade®) is a chimeric (part mouse, part human) antibody given by intravenous infusion every four to eight weeks. Certolizumab pegol (Cimzia®) is a pegylated antibody fragment with minimal placental transfer—an important safety advantage in pregnancy. Golimumab (Simponi®) is a fully human antibody given as a once-monthly subcutaneous injection. Class-wide safety concerns for TNFi include increased risk of serious infections (odds ratio 1.42 versus conventional DMARDs), tuberculosis reactivation (mandatory TB screening with interferon-gamma release assay—IGRA or skin test before initiation), rare risk of demyelinating diseases, and lupus-like reactions. TNFi should be avoided or used with great caution in patients with moderate-to-severe heart failure (New York Heart Association—NYHA Class III or IV).

IL-6 receptor inhibitors block IL-6, an inflammatory cytokine that drives both joint inflammation and systemic features of RA, including fatigue and anemia. Tocilizumab (Actemra®) was the first IL-6 receptor inhibitor approved; it can be given as an intravenous or subcutaneous injection and has demonstrated superior efficacy to adalimumab as a monotherapy (without methotrexate) in the ADACTA trial. Sarilumab (Kevzara®) is given as a subcutaneous injection every two weeks and was superior to adalimumab monotherapy in the MONARCH trial. IL-6 inhibitor side effects include neutropenia, elevated liver enzymes, lipid changes (cholesterol monitoring required), and rare gastrointestinal perforations.

Abatacept (Orencia) blocks the T-cell co-stimulation signal that activates autoreactive T-cells. It is given by intravenous infusion or subcutaneous injection and is specifically preferred in patients with chronic obstructive pulmonary disease—COPD (lower pulmonary adverse events compared to TNFi) and in patients with RA-associated interstitial lung disease. The ATTEST trial demonstrated a lower serious infection rate and lower infusion reactions compared to infliximab. Rituximab (Rituxan®) depletes CD20-positive B-cells through intravenous infusion (two 1,000 mg infusions, 15 days apart). The 2021 ACR guideline reserves rituximab for patients with an inadequate response to TNFi or for those with a history of lymphoma (where TNFi is relatively contraindicated). Seropositive RF-positive patients respond particularly well. Important precautions: rituximab is contraindicated in hepatitis B surface antigen-positive (HBsAg+) patients due to risk of fulminant viral reactivation; there is a rare risk of progressive multifocal leukoencephalopathy (PML).

Janus kinase inhibitors (JAKi) are oral small-molecule drugs that block Janus kinase (JAK) enzymes inside immune cells, interrupting the intracellular signaling pathway that multiple inflammatory cytokines use to produce their downstream effects. Three are FDA-approved for RA. Tofacitinib (Xeljanz®, 5 mg twice daily or 11 mg extended-release once daily) inhibits JAK1 and JAK3; the ORAL Strategy trial demonstrated non-inferiority to adalimumab plus methotrexate. Baricitinib (Olumiant®, 4 mg once daily) inhibits JAK1 and JAK2; the RA-BEAM trial showed superiority to adalimumab plus methotrexate for disease activity reduction. Upadacitinib (Rinvoq®, 15 mg once daily) selectively inhibits JAK1 approximately 74-fold over JAK2; the SELECT-COMPARE trial showed superiority to adalimumab for ACR50 response (45% versus 29%). In 2021, the FDA issued a Black Box Warning for the entire JAK inhibitor class based on the ORAL Surveillance trial of tofacitinib, which identified increased risks of serious cardiovascular events (major adverse cardiovascular events—MACE), malignancy, venous thromboembolism (blood clots), and serious infections compared to TNFi in patients aged 50 years and older with additional cardiovascular risk factors. The ACR 2021 guideline strongly recommends against using JAKi over methotrexate as initial therapy, but considers them equivalent to bDMARDs after csDMARD failure, with patient comorbidities and the JAK safety profile guiding the choice.

Oral prednisone and intravenous methylprednisolone are among the most rapidly effective anti-inflammatory agents available and are used as bridge therapy—providing rapid symptom relief while DMARDs reach their full effect over weeks to months. The ACR 2021 guideline strongly recommends against long-term glucocorticoid use (three months or longer) due to cumulative side effects, including osteoporosis, diabetes, hypertension, weight gain, cataracts, and infections. Short courses of less than three months are conditionally acceptable as bridge therapy. Intra-articular corticosteroid injections—methylprednisolone or triamcinolone injected directly into one or two actively inflamed joints—are used for localized flares and are an adjunct to, not a substitute for, systemic DMARD therapy.

Biosimilars are biologic medications produced to be highly similar to FDA-approved reference biologics (called originator or reference products). The ACR 2021 guideline considers FDA-approved biosimilars equivalent to their originator products. As of 2021, more than 15 FDA-approved biosimilars are available for RA-relevant biologics, including multiple biosimilars for adalimumab (Amjevita®, Hadlima®, Hulio®, Hyrimoz®, Cyltezo®, Abrilada®, and others), etanercept (Erelzi®, Eticovo®), infliximab (Inflectra®, Renflexis®, Avsola®, Ixifi®), and rituximab (Truxima®, Ruxience®, Riabni®). Biosimilars offer the same clinical benefit as originator products, often at lower cost.

The rate of major joint surgery for RA has declined substantially as more effective DMARD therapy has reduced the progression to severe structural damage. Surgery is indicated when medical management fails to control pain and functional loss, or when irreversible structural damage has occurred that impairs quality of life. Synovectomy—surgical removal of the inflamed joint lining—is performed for persistent synovitis in a single joint or small number of joints that has not responded to six or more months of medical therapy. Sites include the wrist, knee, shoulder, and tendon sheaths. Total hip arthroplasty and total knee arthroplasty achieve equivalent pain relief in RA as in osteoarthritis, though rehabilitation is typically slower. Wrist arthrodesis (fusion of the wrist joint) eliminates pain in severely destroyed wrists by sacrificing motion for stability. Metacarpalphalangeal (MCP) joint arthroplasty using silastic silicone implants (the Swanson procedure) corrects ulnar deviation and knuckle subluxation, improving both cosmesis and hand function. Tendon repair or transfer procedures address extensor and flexor tendon ruptures from chronic tenosynovitis. Cervical spine fusion is required for atlantoaxial instability (measured as 3 mm or more of subluxation on flexion-extension X-ray) when there is neurological risk from potential spinal cord compression.

Assistive technology is a central component of RA management and is conditionally recommended by the ACR 2022 guidelines. Wrist and finger splints stabilize inflamed joints and reduce pain—resting splints for overnight use, functional splints for daytime activity stabilization. Foot orthotics (metatarsal pads, custom insoles) address forefoot deformity and pain. Compression gloves may reduce morning stiffness and hand swelling. Adaptive equipment—built-up handles on utensils and pens, button hooks, reachers, jar openers, and sock aids—preserves independence in daily activities by reducing the joint force required. Canes, walkers, and wheelchairs support mobility in advanced disease. Environmental adaptations, including grab bars, raised toilet seats, stair lifts, and shower chairs, reduce fall risk and energy expenditure.

RA-associated interstitial lung disease (ILD) is treated with antifibrotic therapy (nintedanib, approved for RA-ILD based on the INBUILD trial in 2019), mycophenolate mofetil, or rituximab, managed through a multidisciplinary ILD clinic. Cardiovascular disease management includes statins, antihypertensives, antiplatelet agents, and a preference for non-TNFi biologic therapies in patients with significant heart failure. Osteoporosis is treated with bisphosphonates (alendronate, zoledronic acid) or denosumab, along with calcium and vitamin D supplementation, particularly for patients on glucocorticoids. Depression and anxiety—present in approximately 38% of RA patients over their lifetime—are treated with CBT, selective serotonin reuptake inhibitors (SSRIs), and referral to mental health services; effective RA disease control itself improves mental health outcomes. Secondary Sjogren’s sicca symptoms are managed with artificial tears and pilocarpine for dry eyes and mouth.

Rheumatoid disease is a lifelong condition that affects every dimension of daily life—from basic self-care and household tasks to employment, relationships, and emotional well-being. The range of severity is wide: some people achieve and sustain remission and lead fully active lives with minimal limitations, while others experience a more progressive course despite multiple lines of therapy. Fatigue is among the most disabling features and is often underrecognized by both patients and clinicians. Work disability is a meaningful burden—adults with RA are less likely to be employed, and occupational impact is greatest in physically demanding jobs. The great majority of RA patients who begin treatment early and engage consistently with a rheumatologist-led, treat-to-target approach maintain meaningful function and independence throughout their lives.

Flares—periods of increased disease activity—will occur throughout the course of RA. Learning to recognize personal flare triggers (stress, infection, missed medications, physical overexertion), having a clear action plan with your rheumatologist for managing them, and not waiting weeks before seeking evaluation of a significant worsening are all practical skills that improve long-term outcomes. The emotional weight of living with a chronic, unpredictable condition is real, and depression and anxiety are more common in RA than in the general population. Addressing these through CBT, peer support groups such as those offered through the Arthritis Foundation® (arthritis.org), and mental health referral when needed is as important as managing joint disease. Cardiovascular health requires active, ongoing attention—routine blood pressure monitoring, cholesterol management, aerobic exercise, and smoking cessation are not optional extras but central components of RA care that directly protect life expectancy.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of rheumatoid arthritis and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.